Compugen (NASDAQ:CGEN) CEO Sells $12,431.25 in Stock

Compugen Ltd. (NASDAQ:CGEN) CEO Eran Ophir sold 5,625 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $2.21, for a total transaction of $12,431.25. Following the sale, the chief executive officer owned 11,375 shares of the company’s stock, valued at approximately $25,138.75. This represents a 33.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Compugen Stock Performance

Shares of Compugen stock opened at $2.26 on Monday. The company has a 50-day simple moving average of $1.96 and a two-hundred day simple moving average of $1.78. The stock has a market capitalization of $213.68 million, a PE ratio of 6.11 and a beta of 2.77. Compugen Ltd. has a 52-week low of $1.13 and a 52-week high of $2.38.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings results on Monday, March 2nd. The biotechnology company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.55. The firm had revenue of $67.33 million for the quarter, compared to analysts’ expectations of $14.30 million. Compugen had a net margin of 48.57% and a return on equity of 55.68%. As a group, equities research analysts forecast that Compugen Ltd. will post -0.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CGEN has been the subject of a number of research analyst reports. Truist Financial raised Compugen to a “strong-buy” rating in a report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compugen in a report on Wednesday, January 21st. Wall Street Zen upgraded Compugen from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Finally, HC Wainwright initiated coverage on Compugen in a research report on Wednesday, January 7th. They issued a “buy” rating and a $4.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.00.

Institutional Investors Weigh In On Compugen

Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC boosted its stake in shares of Compugen by 1,077.0% in the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after buying an additional 359,785 shares during the last quarter. XTX Topco Ltd purchased a new stake in Compugen during the fourth quarter valued at $104,000. Marshall Wace LLP lifted its holdings in Compugen by 135.7% in the fourth quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock valued at $163,000 after acquiring an additional 61,202 shares during the period. WINTON GROUP Ltd bought a new position in Compugen in the fourth quarter valued at about $84,000. Finally, Renaissance Technologies LLC boosted its position in Compugen by 3.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company’s stock worth $2,229,000 after purchasing an additional 51,565 shares during the last quarter. 12.22% of the stock is currently owned by hedge funds and other institutional investors.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.